Key facts
- ARFICUS’s last known valuation is $130.0M (Jan 2025).
- It has raised $52.5M; the latest was Accelerator/Incubator in Mar 2025.
- Notable investors include Vertex Ventures Israel, Action For India, Drishti CPS Foundation, IAC, International Accelerator — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for ARFICUS
- ·The full record, as it builds
Funding rounds
No funding rounds for ARFICUS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ARFICUS
Developer of a generative AI-powered software as a medical device (SAMD) designed to revolutionize healthcare diagnostics and analysis. The platform, "MEDHINI," offers rapid and accurate genomics-based multimodal solutions for diagnostics, antimicrobial resistance, virtual clinical trials, climate change impact on human health, and insure-tech underwriting across pulmonology, neurology, nephrology, cardiology, and oncology, enabling affordable, technology-driven healthcare accessibility with a focus on social impact.
- Sector
- Healthcare
- HQ
- Jaipur, India
- Founded
- 2019
- Employees
- 186
- Website
- arficus.com/
- Ownership
- Privately Held (backing)
ARFICUS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ARFICUS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ARFICUS in its N-PORT filings yet. We sweep new filings monthly.